Bristol Myers Squibb's lung cancer treatment Krazati showed median progression-free survival of 5.5 months, below analyst expectations.
Bristol Myers Squibb's lung cancer treatment, Krazati, delayed tumor growth by less than seven weeks in a clinical trial, falling short of analyst expectations. Krazati, which competes with Amgen's Lumakras, showed a median progression-free survival of 5.5 months compared to 3.8 months for standard chemotherapy in the study. While the results were statistically significant, they were below analyst projections.
June 01, 2024
3 Articles